388 related articles for article (PubMed ID: 11860367)
1. Chemotherapy of Chagas disease.
Urbina JA
Curr Pharm Des; 2002; 8(4):287-95. PubMed ID: 11860367
[TBL] [Abstract][Full Text] [Related]
2. Ergosterol biosynthesis and drug development for Chagas disease.
Urbina JA
Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():311-8. PubMed ID: 19753490
[TBL] [Abstract][Full Text] [Related]
3. [The chemotherapy of Chagas disease].
Stoppani AO
Medicina (B Aires); 1999; 59 Suppl 2():147-65. PubMed ID: 10668258
[TBL] [Abstract][Full Text] [Related]
4. A decade of targets and patented drugs for chemotherapy of Chagas disease.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):216-59. PubMed ID: 21824073
[TBL] [Abstract][Full Text] [Related]
5. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2016; 11(2):74-173. PubMed ID: 27784230
[TBL] [Abstract][Full Text] [Related]
6. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches.
Urbina JA
Acta Trop; 2010; 115(1-2):55-68. PubMed ID: 19900395
[TBL] [Abstract][Full Text] [Related]
7. Specific treatment of Chagas disease: current status and new developments.
Urbina JA
Curr Opin Infect Dis; 2001 Dec; 14(6):733-41. PubMed ID: 11964893
[TBL] [Abstract][Full Text] [Related]
8. Chagas disease: progress and new perspectives.
Sánchez-Sancho F; Campillo NE; Páez JA
Curr Med Chem; 2010; 17(5):423-52. PubMed ID: 20015038
[TBL] [Abstract][Full Text] [Related]
9. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.
Molina J; Martins-Filho O; Brener Z; Romanha AJ; Loebenberg D; Urbina JA
Antimicrob Agents Chemother; 2000 Jan; 44(1):150-5. PubMed ID: 10602737
[TBL] [Abstract][Full Text] [Related]
10. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi.
Molina J; Brener Z; Romanha AJ; Urbina JA
J Antimicrob Chemother; 2000 Jul; 46(1):137-40. PubMed ID: 10882704
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
Monteiro ME; Lechuga G; Lara LS; Souto BA; Viganó MG; Bourguignon SC; Calvet CM; Oliveira FOR; Alves CR; Souza-Silva F; Santos MS; Pereira MCS
Eur J Med Chem; 2019 Nov; 182():111610. PubMed ID: 31434040
[TBL] [Abstract][Full Text] [Related]
12. Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Changas desease.
Cazzulo JJ
Curr Top Med Chem; 2002 Nov; 2(11):1261-71. PubMed ID: 12171584
[TBL] [Abstract][Full Text] [Related]
13. Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment.
Menna-Barreto RF; de Castro SL
Curr Top Med Chem; 2017; 17(10):1212-1234. PubMed ID: 27784255
[TBL] [Abstract][Full Text] [Related]
14. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host.
Maya JD; Cassels BK; Iturriaga-Vásquez P; Ferreira J; Faúndez M; Galanti N; Ferreira A; Morello A
Comp Biochem Physiol A Mol Integr Physiol; 2007 Apr; 146(4):601-20. PubMed ID: 16626984
[TBL] [Abstract][Full Text] [Related]
15. Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
Palace-Berl F; Pasqualoto KFM; Zingales B; Moraes CB; Bury M; Franco CH; da Silva Neto AL; Murayama JS; Nunes SL; Silva MN; Tavares LC
Eur J Med Chem; 2018 Jan; 144():29-40. PubMed ID: 29247858
[TBL] [Abstract][Full Text] [Related]
16. Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease.
Beltran-Hortelano I; Perez-Silanes S; Galiano S
Curr Med Chem; 2017 May; 24(11):1066-1138. PubMed ID: 28025938
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.
Soeiro Mde N; de Souza EM; da Silva CF; Batista Dda G; Batista MM; Pavão BP; Araújo JS; Aiub CA; da Silva PB; Lionel J; Britto C; Kim K; Sulikowski G; Hargrove TY; Waterman MR; Lepesheva GI
Antimicrob Agents Chemother; 2013 Sep; 57(9):4151-63. PubMed ID: 23774435
[TBL] [Abstract][Full Text] [Related]
18. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
[TBL] [Abstract][Full Text] [Related]
19. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease.
Urbina JA; Payares G; Sanoja C; Lira R; Romanha AJ
Int J Antimicrob Agents; 2003 Jan; 21(1):27-38. PubMed ID: 12507835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]